Michael Aigner is a Co-Founder of KOSMAS and Head of the Cell Processing Unit GMP Facility at the University Hospital Erlangen. His expertise includes developing and enhancing cellular therapies utilizing antibody derived molecules and adoptive transfer of ex vivo stimulated or genetically modified T cells (CAR T).

 For more than 20 years Dr. Aigner has been working in the field of tumor immunology, focusing on the use of NK and T cells as therapeutics in leukemia and lymphomas. 

 Dr. Aigner is a molecular biologist with a PhD in Medical Microbiology from the University of Regensburg, Germany.